Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 932-389-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Single oral doses of [14C]-labelled cyhalothrinto rats (1 or 25 mg/kg) using two different [14C]-labelsare incompletely absorbed following oral administration, and the absorbed dose is extensively metabolised and rapidly excreted. Most of the radioactive dose was rapidly eliminated in the first 24 hours after dosing, but a small proportion of an oral dose (2 – 3%) was still retained in the animals after seven days. Radiolabelled components were distributed to most tissues and were detectable seven days after dosing. Residues in fat were many-fold higher than in any other tissue and were very similar with both [14C]-forms of cyhalothrin indicating that the fat residue may be due to unchanged cyhalothrin. The highest concentration was in brown fat.The concentration of radioactivity in brown fat and other tissues, with the exception of white fat, declined relatively quickly. The peak concentration of radioactivity in white fat increased in proportion to the administered dose. Apart from in the gonads, where levels in ovaries were higher than in testes, no marked sex differences were noted in the tissue distribution of [14C]-benzyl labelled cyhalothrin.
Two repeat dose oral studies were performed in the rat. In the first rats were given 14 consecutive daily oral doses of 1 mg/kg [14C]-benzyl or [14C]-cyclopropyl labelled cyhalothrin. Approximately 90% of the cumulated dose was recovered in urine and faeces by 7 days after the last dose. The carcass residue at 7 days was due almost entirely to residues in the fat. These fat residues were shown to be principally unchanged cyhalothrin present at a concentration of 3.3mg equivalents/g. In the second study groups of male rats were each given up to 119 consecutive daily oral doses of 1 mg/kg [14C]-cyclopropyl labelled cyhalothrin. The concentration of cyhalothrin in fat increased throughout the dosing period to a maximum of approximately 10mg equivalents/g, whereas those in blood, liver and kidneys appeared to plateau and were significantly lower. On cessation of dosing the radioactive residues in tissues other than fat declined rapidly indicating rapid elimination.
It is established that cyhalothrin, in common with other synthetic pyrethroids, can accumulate in abdominal fat with repeated dosing, but the amount accumulated is low. Assuming that fat constitutes 15% of the bodyweight, the total amount of cyhalothrin retained after repeated administration would be equivalent to approximately 1.5 times the daily dose. The total amount of retained cyhalothrin is therefore unlikely to present a greater hazard than a single dose of the same magnitude.
Cyhalothrin was variably absorbed after oral administration to dogs. The degree of absorption was difficult to assess but seems to cover at least the range 48 - 80%, this being attributable to inter-animal variation. Excretion of radioactivity after both oral and intravenous dosing was initially rapid, with most of the dosed radioactivity excreted in the first 48 hours after dosing. However, excretion remained incomplete after 7 days with a mean of between 82 and 93% recovered in this time. The absorbed material was extensively metabolised and eliminated via the kidney and in bile.
Apart from the fat residue, any absorbed cyhalothrin was extensively metabolised. The major pathway of metabolism in both rat and dog was ester cleavage followed by conjugation of the cleaved metabolites with either glucuronic acid or sulphate.
The major radioactive component in urine of rats dosed with [14C]-benzyl labelled cyhalothrin was the sulphate conjugate of 3-(4'-hydroxyphenoxy) benzoic acid (compound XXIII). Un-conjugated compound XXIII and 3-phenoxybenzoic were minor metabolites. The major radioactive component in urine of rats dosed with [14C]-cyclopropyl labelled cyhalothrin was the glucuronide conjugate of (1RS)-cis-3-(2-chloro-3,3,3-trifluoropropenyl)-2,2-dimethylcyclopropane carboxylic acid. One of the minor metabolites also appeared to be a glucuronide conjugate, which was tentatively identified as a hydroxylated analogue of cyclopropane acid.
Metabolites identified in the dog were 3-phenoxybenzoic acid mainly as its glucuronide conjugate, but also as a glycine conjugate; 3-(4'-hydroxyphenoxy)benzoic acid mainly as the sulphate conjugate and (1RS)-cis-3-(2-chloro-3,3,3-trifluoropropenyl)-2,2-dimethylcyclopropane carboxylic acid and the corresponding glucuronide.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.